Cerus Corporation (CERS)

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus' entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for plat.

CERS develops the Intercept Blood System for platelets, plasma, and IFC. These are valuable offerings for blood transfusions. CERS Intercept provides a pathogen-reduced transfusion product suite that directly address blood safety worldwide. IFC allows for room-temperature fibrinogen support that sharply reduces wasted product and turnaround times.

Connor Clark and Lunn Investment Management Ltd. boosted its holdings in Cerus Corporation (NASDAQ: CERS) by 49.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 296,099 shares of the biotechnology company's stock after acquiring an additional 97,592 shares during

Cerus Corporation ( CERS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Timothy Lee William Greenman - President, CEO & Chairman Vivek Jayaraman - Chief Operating Officer Kevin Green - VP of Finance & CFO Conference Call Participants Junwoo Park - Cantor Fitzgerald & Co., Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2025 Earnings Conference Call.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, at the 2025 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in San Diego, California from October 25 through October 28. The AABB Annual Meeting attracts healthcare professionals, scientists, and.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Rela.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transf.

Cerus Corporation (NASDAQ:CERS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Kevin D. Green - VP of Finance & CFO Vivek K.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generati.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, and, as lyophilized, LyoIFC) to treat bleeding due to trauma. This additional award is additive t.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory review for INTERCEPT RBC is advancing ahead of plan and that TÜV-SÜD, our Notified Body, has completed their review of the clinical module and transferred information to the State Institute for Drug Control (SÚKL) in the Czech Republic, for consultation. Reaching this meaningful milestone enables SÚKL.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, “Give blood, give hope: together we save lives” is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and exp.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relati.